Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

SUNNYVALE, Calif., Feb. 4, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported recent developments and financial results for its fiscal second quarter that ended December 31, 2010.Recent Developments & Highlights

  • Broad Clinical Development Progress for Btk Inhibitor PCI-32765 in B-cell malignanciesPharmacyclics has designed a broad Phase II Program in mantle cell lymphoma, chronic lymphocytic leukemia and diffuse large B-cell lymphoma to inform the Phase III program and regulatory path for PCI-32765. Throughout 2011 we will closely monitor these Phase II studies for confirmatory efficacy and safety signals to establish our regulatory approval strategy in a timely manner.  Please refer to our website on the key trials listed below.-Mantle Cell Lymphoma (MCL) Our Phase IA results in the MCL subset presented at the 2010 American Society of Hematology (ASH) Meeting showed promising activity. We therefore designed a Phase II program which includes 1) an evaluation of PCI-32765 as a single agent in 2 groups (cohorts) of patients with relapsed or refractory disease, those who have failed bortezomib and those who have not yet received bortezomib and 2) a safety study of PCI-32765 in combination with bortezomib. The single agent trial protocol has been developed and we expect to enroll a total of approximately 100 patients, beginning in Q1 of calendar year 2011.-Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL) The Phase IB/II CLL/SLL program is well underway; to date we have dosed 75 patients and plan to complete enrollment by adding another 7 patients during the remainder of Q1 of calendar 2011. We are also evaluating the safety of PCI-32765 in combination with ofatumumab in a Phase IB/II study of patients with relapsed/refractory CLL/SLL. We began enrollment in this study in January of 2011 and expect to dose up
    '/>"/>


  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
    2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
    3. Pharmacyclics, Inc. Rights Offering Oversubscribed
    4. Pharmacyclics Announces Subscription Price for Rights Offering
    5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
    6. Pharmacyclics Files Registration Statement for Rights Offering
    7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
    8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
    9. Pharmacyclics Secures $5.0 Million in Debt Financing
    10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
    11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
    (Date:8/19/2014)... CA (PRWEB) August 19, 2014 Robin ... Parkinson’s disease can take on an individual. Symptoms ... decreased facial expression, problems swallowing and severe depression. ... the dying off of dopamine producing neurons of the ... from a disease that slowly and progressively gets worse, ...
    (Date:8/19/2014)... Aug. 19, 2014 Research ... of the "Spectroscopy Equipment and Accessories ... to their offering. This ... Equipment and Accessories in US$ Thousands by ... spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared ...
    (Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
    Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
    ... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
    ... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
    ... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
    Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
    (Date:8/19/2014)... To improve students, chances of completing introductory ... of Houston (UH) implemented a comprehensive student success ... for failure. , Through a grant from ... Department of Biology and Biochemistry embarked on a ... Biology" for non-majors and "Introductory Biology" for science ...
    (Date:8/19/2014)... It,s not a lemur. It,s not an African Bush Baby ... tiny, adorable and downright "cool" primate from Southeast Asia. , ... with," said Rafe Brown, curator-in-charge at the University of Kansas, ... extremely cute, furry body; a long tail with a furry ... tips that look a bit like the disks on the ...
    (Date:8/19/2014)... a biomarker strongly associated with basal-like breast cancer, ... many types of chemotherapy. The biomarker, a protein ... therapeutics designed to treat this often deadly cancer. ... The Cancer Genome Atlas, molecular biologists Curt M. ... and bioinformatics techniques to detect patterns of gene ...
    Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
    ... The decline of large predators and other "apex consumers" at ... the planet. The finding is reported by an international ... of the journal Science . The study looked ... and marine ecosystems and concluded "the loss of apex consumers ...
    ... 14, 2011 Two studies published in the current ... that consuming in-shell pistachios is a weight-wise approach to ... curb consumption and decrease calorie intake. ... pistachios ate 41-percent fewer calories compared to those who ...
    ... East Coast may be at risk to higher sea levels ... years, according to a new study by NOAA. The ... surges along the East Coast during the 2009-2010 El Nio ... NOAA,s Center for Operational Oceanographic Products and Services, examined water ...
    Cached Biology News:Loss of large predators caused widespread disruption of ecosystems 2Loss of large predators caused widespread disruption of ecosystems 3In-shell pistachios: The original 'slow food?' 2In-shell pistachios: The original 'slow food?' 3Strong El Niño could bring increased sea levels, storm surges to US East Coast 2
    BD BaculoGold Max-XP Insect Cell Medium 1 Liter...
    Newborn Bovine Serum Heat-Inactivated...
    Performance, mycoplasma, virus, and endotoxin tested...
    Bethyl Laboratories Ready-To-Use IHC Bluing Reagent is used following IHC hematoxylin counterstaining with immunohistochemical procedures. Shelf-Life: 1 year from date of receipt...
    Biology Products: